Tevogen Bio Holdings Inc. (TVGN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Tevogen Bio Holdings Inc. (TVGN) has a cash flow conversion efficiency ratio of 0.338x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.01 Million) by net assets ($-8.89 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see TVGN company net worth for the company's overall valuation and market capitalisation.
Tevogen Bio Holdings Inc. - Cash Flow Conversion Efficiency Trend (2022–2026)
This chart illustrates how Tevogen Bio Holdings Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Tevogen Bio Holdings Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Tevogen Bio Holdings Inc. ranked by their cash flow conversion efficiency. Explore TVGN operating cash flow to net income to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Clene Inc.
NASDAQ:CLNN
|
0.104x |
|
Akin Tekstil AS
IS:ATEKS
|
0.001x |
|
Rank Progress S.A.
WAR:RNK
|
0.006x |
|
Francotyp-Postalia Holding AG
F:FPH
|
0.005x |
|
FreeCast, Inc. Class A Common Stock
NASDAQ:CAST
|
0.408x |
|
SMCore.Inc
KQ:007820
|
-0.082x |
|
Carlos Casado
BA:CADO
|
0.014x |
|
Senko Co. Ltd
KQ:347000
|
0.022x |
Annual Cash Flow Conversion Efficiency for Tevogen Bio Holdings Inc. (2022–2026)
The table below shows the annual cash flow conversion efficiency of Tevogen Bio Holdings Inc. from 2022 to 2026. View Tevogen Bio Holdings Inc. share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2026-06-30 | $-8.23 Million | $-12.33 Million | 1.497x | -16.72% |
| 2025-06-30 | $-6.67 Million | $-12.00 Million | 1.798x | +1977.65% |
| 2024-06-30 | $-94.43 Million | $-8.17 Million | 0.087x | -66.06% |
| 2023-06-30 | $-33.95 Million | $-8.66 Million | 0.255x | -20.31% |
| 2022-06-30 | $-16.49 Million | $-5.27 Million | 0.320x | -- |
About Tevogen Bio Holdings Inc.
Tevogen Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients; and in Phase 1 clinical trial to treat acute SARS-CoV-2 patients with B… Read more